Incruse Ellipta is a medication used to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1][2]. It is a long-acting muscarinic antagonist (LAMA) that works by relaxing the muscles around the airways in the lungs, making it easier to breathe [1][2][3]. The active ingredient in Incruse Ellipta is umeclidinium [1].
How is Incruse Ellipta administered?
Incruse Ellipta is delivered via an inhalation device called the Ellipta inhaler [1][4]. Patients inhale one puff of the medication once daily [1][2]. It is important to follow the specific instructions provided with the inhaler for proper use [4].
What is the mechanism of action for umeclidinium?
Umeclidinium is a selective muscarinic receptor antagonist. It blocks the action of acetylcholine at M3 muscarinic receptors in the airway smooth muscle. This blockade prevents acetylcholine from causing bronchoconstriction, thereby leading to bronchodilation and improved airflow [3][5].
When does patent protection for Incruse Ellipta expire?
Information regarding the specific patent expiry dates for Incruse Ellipta and its active ingredient, umeclidinium, is available through specialized patent databases [6]. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity periods, which can indicate when generic versions may become available [6].
What are the common side effects of Incruse Ellipta?
Common side effects associated with Incruse Ellipta include nasopharyngitis (common cold symptoms), and upper respiratory tract infection [1][2]. Less common side effects may also occur [1]. Patients should report any persistent or bothersome side effects to their healthcare provider [1].
What are the risks associated with Incruse Ellipta?
While generally well-tolerated, Incruse Ellipta carries certain risks. These can include paradoxical bronchospasm, where breathing suddenly worsens after using the inhaler. It also poses risks for patients with narrow-angle glaucoma or urinary retention, as muscarinic antagonists can exacerbate these conditions [1][3].
How does Incruse Ellipta compare to other COPD medications?
Incruse Ellipta is a LAMA and is often prescribed as a maintenance treatment for COPD. It can be used alone or in combination with other COPD medications, such as long-acting beta-agonists (LABAs) or inhaled corticosteroids (ICS) [1][3]. Its efficacy and side effect profile are compared with other available bronchodilators for COPD management in clinical studies [3][5].
Can Incruse Ellipta be used for asthma?
Incruse Ellipta is indicated for the treatment of COPD and is not approved for the management of asthma [1][2].
Who manufactures Incruse Ellipta?
Incruse Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
What are the clinical trial results for Incruse Ellipta?
Clinical trials have demonstrated that Incruse Ellipta improves lung function in patients with COPD compared to placebo [3][5]. Studies have evaluated its impact on endpoints such as forced expiratory volume in one second (FEV1) and rates of exacerbations [5].
What is the cost of Incruse Ellipta?
The cost of Incruse Ellipta can vary depending on insurance coverage, pharmacy pricing, and available patient assistance programs [7]. Information on pricing and potential savings can often be found through pharmaceutical company websites or patient support services [7].
What is the difference between Incruse Ellipta and other LAMAs?
Incruse Ellipta contains umeclidinium, which is a LAMA. Other LAMAs used for COPD include tiotropium, aclidinium, and glycopyrronium. While they share the same basic mechanism of action, they may differ in their receptor binding affinity, duration of action, pharmacokinetic profiles, and potential side effects [3][5].
Can generic versions of Incruse Ellipta be available?
The availability of generic versions of Incruse Ellipta depends on the expiration of its patents and any associated exclusivity periods [6]. Once these protections expire, other pharmaceutical companies may seek regulatory approval to market generic equivalents [6].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205274s000lbl.pdf
[2] https://www.incruse.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837187/
[4] https://www.incruse.com/how-to-use-ellipta-inhaler.html
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1311268
[6] https://drugpatentwatch.com/
[7] https://www.goodrx.com/incruse-ellipta